Source: Annual Congress 2012 - Tuberculosis: clinical findings III
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Naryshkina, S. Medvedev, E. Pushkareva (Novosibirsk, Russian Federation). Antituberculosis chemotherapy toxicity reduction. Eur Respir J 2012; 40: Suppl. 56, 2623

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008 Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Hepatotoxicity of antituberculosis chemotherapy in patients with liver cirrhosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011 Role of chemotherapy and radiation therapy Source: Annual Congress 2012 - PG10 An update on mesothelioma diagnostics and treatment Year: 2012 Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Source: Eur Respir J, 51 (1) 1701737; 10.1183/13993003.01737-2017 Year: 2018 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006 The effectiveness of pegfilgrastim in preventing leucopenia in patients with lung cancer under chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy Source: Eur Respir J 2001; 18: 243-245 Year: 2001 Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005